Vowst Prior Authorization Criteria - Medicare Part D
Prior Authorization Criteria for Approval
Vowst will be approved when ALL of the following are met:
-
The requested medication will be used to prevent the recurrence of Clostridioides difficile infection (CDI)
AND -
The patient has had a confirmed diagnosis of recurrent CDI as defined by greater than or equal to 3 episodes of CDI in a 12 month period
AND -
The patient has completed a standard of care antibiotic regimen (e.g., vancomycin, fidaxomicin) for recurrent CDI at least 2 to 4 days before initiating treatment with the requested medication
AND -
The patient will NOT be using the requested medication in combination with any antibiotic regimen for any indication
AND -
The patient is within the FDA labeled age for the requested medication
AND -
The prescriber is a specialist in the area of the patient’s diagnosis (e.g., infectious disease, gastroenterologist) or the prescriber has consulted with a specialist in the area of the patient’s diagnosis
AND -
ONE of the following:
-
The requested quantity (dose) does NOT exceed the program quantity limit
OR -
BOTH of the following:
- The requested quantity (dose) is greater than the program quantity limit
AND - The prescriber has provided information in support of therapy with a higher dose for the requested indication
- The requested quantity (dose) is greater than the program quantity limit
-
Length of Approval: 12 months